September 18th 2021
Current approaches to precision medicine in oncology have been fruitful, but require better integration and utilization of available resources to inform sustainable and effective drug development and clinical care, according to Andre Goy, MD.
Studies Add to Evidence of Utility of Blood-Based Biomarkers in NSCLC
Evidence is increasing that blood-based biomarkers have predictive utility in advanced non–small cell lung cancer. Going further, blood-based next-generation sequencing appears to have clinical utility in selecting targeted treatment in this setting.
Larotrectinib Elicits Clinically Meaningful PFS Improvement Through GMI in TRK Fusion+ Cancers
Larotrectinib demonstrated a clinically meaningful improvement in progression-free survival compared with time to progression on prior treatment in patients with TRK fusion–positive cancers using a measure known as the growth modulation index.
Technology Advances Aid Treatment Decisions for Community Oncologists
Molecular testing has become an imperative step in the treatment decision-making process for oncologists, and new technologies and assays are emerging to further help identify tumor abnormalities and at the right time.
CFS® Experts: Novel Therapies and Onco-Genomics Add Heft to Precision Medicine
Co-chairs William K. Oh, MD, Adam M. Brufsky, MD, PhD, and Benjamin P. Levy, MD, preview key topics that will be covered at the 37th Annual CFS®: Innovative Cancer Therapy for Tomorrow symposium.
Emerging Biomarkers for Targeted Agents Show Promise in NSCLC
September 17th 2019Alex A. Adjei, MD, PhD, a professor of oncology and pharmacology at Mayo Clinic, discussed the history of five target genes: NTRK, RET, MET, BRAF, and HER2, as well as the exciting data coming out for the lung cancer subset.
Liquid Biopsy Matches Tissue for NSCLC Treatment Guidance
Patients with advanced non–small cell lung cancer and actionable mutations had similar progression-free survival whether treatment guidance came from tissue or circulating tumor (ct)DNA analysis using the Guardant360 assay, a matched retrospective comparison showed.
Broader NGS Use in Oncology Hinges on Payers, Access, and Education
Using up-front, broadpanel genomic tests that include hundreds of genes can save money and, in some cases, improve outcomes compared with other diagnostic approaches, especially in lung cancer but also increasingly in breast, colorectal, skin, and other cancers.
Dr. Papadimitrakopoulou on Implications of the NILE Trial in NSCLC
August 6th 2019Vassiliki A. Papadimitrakopoulou, MD, professor of medicine, Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, the University of Texas MD Anderson Cancer Center, discusses the implications of the NILE trial in non–small cell lung cancer (NSCLC).
Expert Advocates Universal Genetic Testing in Breast Cancer
August 5th 2019Although research findings have established many applications for genetic information in breast cancer, not enough patients are being tested for the risk of germline mutations and new strategies are needed to broaden the clinical application of genomic advancements.
CMS Should Broaden Coverage for Germline Mutation Testing
July 31st 2019Sometimes referred to as massively parallel sequencing, next-generation sequencing evaluates millions of DNA sequences simultaneously, representing a true revolution compared with traditional, labor-intensive methods in which far less DNA could be sequenced at once.